Champions Oncology, Inc. financial data

Symbol
CSBR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
855 N. Wolfe Street, Suite 619, Baltimore, MD
State of incorporation
DE
Fiscal year end
April 30
Former names
CHAMPIONS BIOTECHNOLOGY, INC. (to 3/30/2011), CHAMPIONS SPORTS INC (to 2/16/2007)
Latest financial report
10-Q - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 76.3 % +5.32%
Debt-to-equity 2.63K % +4.91%
Return On Equity 654 %
Return On Assets 24 %
Operating Margin 10.7 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.8M shares +1.72%
Common Stock, Shares, Outstanding 13.7M shares +0.82%
Entity Public Float 22M USD -21.4%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 13.7M shares +0.79%
Weighted Average Number of Shares Outstanding, Diluted 14.4M shares +5.67%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 58.6M USD +19%
Research and Development Expense 6.91M USD -33.2%
Selling and Marketing Expense 7.01M USD -1.75%
General and Administrative Expense 9.58M USD -13.3%
Operating Income (Loss) 6.29M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6.4M USD
Income Tax Expense (Benefit) -27K USD -139%
Net Income (Loss) Attributable to Parent 6.4M USD
Earnings Per Share, Basic 0.47 USD/shares
Earnings Per Share, Diluted 0.44 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.2M USD -28.3%
Accounts Receivable, after Allowance for Credit Loss, Current 15.8M USD +99.9%
Assets, Current 19.7M USD +49.2%
Operating Lease, Right-of-Use Asset 5.37M USD -17.8%
Goodwill 335K USD 0%
Other Assets, Noncurrent 185K USD 0%
Assets 30.6M USD +14.3%
Accounts Payable, Current 5.09M USD +7.09%
Accrued Liabilities, Current 2.27M USD -6.71%
Contract with Customer, Liability, Current 10.9M USD -18.1%
Liabilities, Current 19.9M USD -9.55%
Operating Lease, Liability, Noncurrent 5M USD -22.3%
Other Liabilities, Noncurrent 285K USD -35.1%
Liabilities 25.2M USD -12.8%
Retained Earnings (Accumulated Deficit) -78.1M USD +7.61%
Stockholders' Equity Attributable to Parent 5.47M USD
Liabilities and Equity 30.6M USD +14.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 311K USD
Net Cash Provided by (Used in) Financing Activities -37K USD +93.7%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 13.8M shares +0.82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 274K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.2M USD -28.3%
Deferred Tax Assets, Valuation Allowance 18.1M USD +8.06%
Deferred Tax Assets, Gross 18.1M USD +8.06%
Operating Lease, Liability 6.44M USD -16.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 11.9M USD -19.6%
Property, Plant and Equipment, Gross 16.7M USD +1.1%
Operating Lease, Liability, Current 1.43M USD +9.89%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.92M USD -1.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.95M USD +1.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.42M USD -22.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.87M USD -1.68%
Deferred Tax Assets, Operating Loss Carryforwards 9.04M USD -7.36%
Unrecognized Tax Benefits 181K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.39M USD -16.6%
Depreciation, Depletion and Amortization 1.54M USD -16.8%
Share-based Payment Arrangement, Expense 786K USD -26.1%